In the context of CRC, these nanomaterials have been applied both to canonical CRC biomarkers such as CEA and to inflammation-related proteins (e.g., CRP, IL6, TNF-α), which are increasingly recognized as contributors to CRC onset and progression. The gene discussed is CEACAM5; the disease is colorectal carcinoma.